ABM 168
Alternative Names: ABM-168Latest Information Update: 28 Sep 2023
At a glance
- Originator ABM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Sep 2023 NMPA approves IND for AMB 168 for Solid tumours
- 28 Sep 2023 ABM Therapeutics plans a phase I trial for Solid tumours (Late-stage disease) in China
- 27 Apr 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05831995)